OncClubAll Oncology News
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid Readouts
Conference CoverageConference Listing
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
PartnersPublications
Consensus ViewpointsInteractive ToolsSponsored
Biomarker ConsortiumSubscribe
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
Spotlight -
  • In-person and virtual events just for HCPs
  • CME Opportunities
Biosimilars
Brain Cancer
Breast CancerBreast Cancer
CAR T-cell Therapy
COVID-19
Disparities in Cancer Care
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary Cancers
Global Oncology
Gynecologic OncologyGynecologic Oncology
Head & Neck Cancers
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Oncology Business Management
Pediatric Oncology
Precision Medicine in Oncology®
Sarcomas
Supportive Care
    • Partners
    • Publications
    • Biomarker Consortium
    • Subscribe
Advertisement
Delving into Updates in Metastatic Hormone-Sensitive Prostate Cancer : Episode 2

Commentary

Video

March 12, 2025

Data From an Age-Related Subgroup Analysis of the ARASENS Trial in mHSPC

Author(s):

Daniel J. George, MD,Matthew Smith, MD, PhD

Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss an age-based subgroup analysis from the ARASENS trial in prostate cancer.

EP: 1.The Evolution of Treatment in Metastatic Hormone-Sensitive Prostate Cancer

Now Viewing

EP: 2.Data From an Age-Related Subgroup Analysis of the ARASENS Trial in mHSPC

EP: 3.Outcomes by Disease Volume: A Subgroup Analysis of the ARANOTE Trial in mHSPC

EP: 4.Findings From a Real-World Analysis of ARPIs in Nonmetastatic CRPC

EP: 5.Ongoing Research to Watch in Prostate Cancer in 2025 and Beyond

EP: 6.Key Prostate Cancer Updates to Emerge From ASCO GU 2025

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss ongoing research to watch in prostate cancer.
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss other key prostate cancer data presented at ASCO GU 2025.
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss data from a real-world analysis for AR inhibitors in nmCRPC.
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss a subgroup analysis from the ARANOTE trial in prostate cancer.
Daniel J. George, MD, and Matthew Smith, MD, PhD, discuss the evolution of treatment for metastatic hormone-sensitive prostate cancer.
William K. Oh, MD
Barry W. Goy, MD
Fred Saad, CQ, MD, FRCS, FCAHS, director, Prostate Cancer Research, Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal; full professor, Department of Surgery, Université de Montréal; uro-oncologist, Urology Department, University of Montreal Health Center
Floortje J. Backes, MD, discusses ongoing research to watch in ovarian cancer.
Floortje J. Backes, MD, discusses other potential roles for mirvatuximab soravtansine and other antibody-drug conjugates in ovarian cancer.
Related Content
Advertisement
177Lu rhPSMA-10.1 Injection in mCRPC | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
March 13th 2025

177Lu rhPSMA-10.1 Injection Generates Favorable Radiation Dosimetry Data in mCRPC

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

FDA
March 4th 2025

FDA Approves 2 Denosumab Biosimilars for Osteoporosis and Cancer-Related Bone Disease

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Pedro Barata, MD, MSc, FACP, on prostate cancer
February 24th 2025

Radioligand Therapies and Emerging Targets Drive Innovation in Prostate Cancer Management

Darolutamide in nmCRPC | Image Credit: © Sebastian Kaulitzki – stock.adobe.com Image
February 24th 2025

Darolutamide Provides Clinical Benefits vs Other AR Inhibitors in Black and White Patients With nmCRPC

Related Content
Advertisement
177Lu rhPSMA-10.1 Injection in mCRPC | Image Credit: © Sebastian Kaulitzki – stock.adobe.com
March 13th 2025

177Lu rhPSMA-10.1 Injection Generates Favorable Radiation Dosimetry Data in mCRPC

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

FDA
March 4th 2025

FDA Approves 2 Denosumab Biosimilars for Osteoporosis and Cancer-Related Bone Disease

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Pedro Barata, MD, MSc, FACP, on prostate cancer
February 24th 2025

Radioligand Therapies and Emerging Targets Drive Innovation in Prostate Cancer Management

Darolutamide in nmCRPC | Image Credit: © Sebastian Kaulitzki – stock.adobe.com Image
February 24th 2025

Darolutamide Provides Clinical Benefits vs Other AR Inhibitors in Black and White Patients With nmCRPC

Latest Conference Coverage

Anti-CD38-CAR-γδ T Cells Show Preclinical Cytotoxicity in Myeloma

MT-8421 Displays Acceptable Safety Profile in First-in-Human Trial for Advanced Solid Tumors

SAR444200 Demonstrates Safety, Signals of Clinical Activity in Advanced GPC3+ HCC, Other Solid Tumors

SAR443216 Engages HER2 With Manageable Toxicity in Advanced HER2+ Solid Tumors

View More Latest Conference Coverage
Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.
Home
About Us
News
Contact